

# Case Report

## Myofibrillar Myopathy with Limb-Girdle Phenotype in a Thai Patient

Teerin Liewluck MD\*,  
Jutatip Kintarak MD\*\*, Tumtip Sangruchi MD\*,  
Duygu Selcen MD\*\*\*, Kongkiat Kulkantrakorn MD\*\*\*\*

\* Department of Pathology and Neurogenetics Network, Faculty of Medicine Siriraj Hospital,  
Mahidol University, Bangkok, Thailand

\*\* Department of Pathology, Faculty of Medicine, Thammasat University, Pathumthani, Thailand

\*\*\* Department of Neurology and Neuromuscular Research Laboratory, Mayo Clinic, Rochester, Minnesota, USA

\*\*\*\* Division of Neurology, Department of Internal Medicine, Faculty of Medicine,  
Thammasat University, Pathumthani, Thailand

---

*Myofibrillar myopathy (MFM) encompasses a genetically and clinically heterogeneous group of inherited or sporadic skeletal muscle disorders characterized pathologically by the presence of myofibrillar dissolution associated with accumulation of myofibrillar degradation products and ectopic expression of multiple proteins especially Z-disk related proteins. Patients with MFM initially present with muscle weakness and commonly developed cardiomyopathy in the advanced stage. To date, mutations of genes encoding Z-disk proteins or proteins maintaining myofibrillar integrity including ZASP, MYOT, DES, FLNC and CRYAB underlie MFM. The authors herein report a 29-year-old Thai woman with a clinical diagnosis of autosomal dominant limb-girdle muscular dystrophy (LGMD1) who has one affected grandmother. The patient was subsequently found to have MFM based on her myopathological findings. Analyses of all MFM-genes known to date revealed no mutations. The current case emphasizes the importance of muscle biopsy in LGMD1 patients and a wide range of phenotypic variations among patients with MFM. The causative genes underlying the majority of MFM remain uncovered. Close monitoring of the cardiac function is crucial to prevent mortality among these patients.*

**Keywords:**  $\alpha$ B-crystallin, Desmin, Filamin C, Limb-girdle muscular dystrophy, LGMD, Myofibrillar myopathy, Myotilin, ZASP

**J Med Assoc Thai 2009; 92 (2): 290-5**

**Full text. e-Journal:** <http://www.mat.or.th/journal>

---

The term “myofibrillar myopathy (MFM)” was originally coined by Nakano et al to cover a variety of myopathies sharing a common finding of abnormal desmin accumulation. It has recently been accepted worldwide to cover a group of clinically and genetically heterogeneous muscle disorders. Those disorders share the pathological findings of initial myofibrillar degradation commencing at the Z-disk leading to disintegration of the sarcomeres and subsequent

abnormal ectopic accumulation of Z-disk related proteins including desmin and other products of degradation<sup>(1, 2)</sup>.

Patients with MFM develop slowly progressive muscle weakness that can involve both proximal and distal muscles at the age of 7 to 77 years (mean 54 years)<sup>(3)</sup>. The majority of patients have predominant proximal muscle involvement, although about 25% of affected individuals could mimic a feature of distal myopathies<sup>(3)</sup>. Cardiomyopathy is present in 17% and is the leading cause of death among these patients<sup>(4)</sup>. MFM could be either sporadic or autosomal dominant inheritance. The serum creatine kinase (CK) level is

---

Correspondence to: Liewluck T, Department of Pathology, Faculty of Medicine, Siriraj Hospital, Mahidol University, 2 Prannok Rd., Bangkok-Noi, Bangkok 10700, Thailand. Phone: 0-2419-7000 ext 6504-5. E-mail: sitll@mahidol.ac.th

**Table 1.** Summary of myofibrillar myopathies (MFM) with identified mutations

Causative gene	Mode of inheritance	Age at onset (years old)	Proportion of MFM caused by this mutation	Extramuscular presentations	CK level	Allelic disorders
ZASP ( <i>LDB3</i> )	AD	44-73	16%	Polyneuropathy (45%), cardiomyopathy (27%)	Normal-6x	Markesbery distal myopathy, dilated cardiomyopathy, late onset multimimicore disease with conduction block
Myotilin ( <i>MYOT</i> )	AD	44-77	10%	Polyneuropathy (100%), cardiomyopathy (50%)	Normal-2x	LGMD1A, spheroid body myopathy, dilated cardiomyopathy, late onset autosomal dominant distal myopathy
Desmin ( <i>DES</i> )	AD, AR	20's-30's	9%	Cardiomyopathy (60%)	Mildly elevated	Dilated cardiomyopathy
Filamin C ( <i>FLNC</i> )	AD	37-57	3%	Polyneuropathy (40%), respiratory compromise (50%), cardiac conduction defect (10%)	2-8x	-
alphaB-crystallin ( <i>CRYAB</i> )	AD	Early-middle adulthood	3%	Cataract, dilated cardiomyopathy, respiratory compromise	Normal-7x	AD congenital posterior polar cataract, dilated cardiomyopathy

AD, autosomal dominant; AR, autosomal recessive; CK, creatine kinase; LGMD, limb girdle muscular dystrophy; MFM, myofibrillar myopathy

normal or mildly to moderately elevated up to 7-fold above the normal limit<sup>(3)</sup>. Electromyography shows myopathic changes in the vast majority of the patients and neuropathic changes in 20% of affected individuals<sup>(3)</sup>.

In Mayo Clinic's cohort of 70 unrelated MFMD patients, only 40% of affected individuals had mutations identified in *ZASP* (*LDB3*), myotilin (*TTID* or *MYOT*), desmin (*DES*),  $\alpha$ B-crystallin (*CRYAB*) and filamin C (*FLNC*) genes<sup>(4)</sup>, which leave the causative genes of the majority of MFMD patients remain uncovered. The Table 1 exhibits the summary of MFMD with mutations of aforementioned genes<sup>(3-13)</sup>. Herein, the authors report the first Thai MFMD patient with autosomal dominant, limb-girdle muscle weakness. Molecular analysis of the aforementioned genes reveals no mutations.

## Case Report

### Clinical summary

A 29-year-old right handed, healthy Thai woman developed difficulty in combing her hair during her first pregnancy at the age of 27 years. Over 2 years, weakness progressed to involve lower extremities leading to difficulty in standing up from a squatting position and difficulty in climbing upstairs. Currently, the patient ambulates with a cane. The patient was the offspring of non-consanguineous marriage and had normal developmental milestones. Family history was relevant for affected maternal grandmother of similar symptoms in her middle age. No other relatives were affected. On the clinic visit, the patient appeared oriented and cooperative. No cataract was seen on ophthalmologic evaluation. Cardiovascular examination was unremarkable. Neurologic examination disclosed normal facial and orbicularis oculi muscle function but weakness of both upper and lower extremities predominantly affecting proximal muscles. Neither atrophy nor hypertrophy was observed. Based on medical research council scale of power (MRC), deltoid, biceps, iliopsoas, gluteus maximus, hip abductors and adductors were grade 3/5, while quadriceps, hamstring, tibialis anterior and gastrocnemius were grade 4/5. The rest of the muscles' strengths were grade 5/5. Deep tendon reflexes were normal. No sensory deficit was noted. Neither joint contracture nor kyphoscoliosis was observed. Laboratory investigations revealed moderately elevated serum CK level (1023 IU/L). EMG test of deltoid, abductor pollicis brevis, quadriceps femoris, and tibialis anterior muscles depicted myopathic changes while nerve conduction study of


median, ulnar, and peroneal nerves was unremarkable. EKG showed normal sinus rhythm.

A muscle sample taken from the biceps brachii was processed in liquid nitrogen-cooled isopentane, with a panel of histochemical stains (hematoxyline and eosin, modified Gomori trichrome, periodic acid-Schiff, oil red O and Congo red), enzyme histochemistry (reduced nicotinamide adenine dinucleotide-tetrazolium reductase or NADH-TR, succinic dehydrogenase or SDH, cytochrome oxidase or COX, myosin ATPase, non-specific esterase, alkaline phosphatase and acid phosphatase), and immunohistochemistry (desmin) as previously described by the authors<sup>(14)</sup>. Muscle biopsy (Fig. 1) showed moderate variation in fiber size with sparse perimysial lymphocytes infiltration but no myonecrosis. Rimmed vacuoles and typical cytoplasmic bodies were conspicuous in some muscle fibers. Numerous myofibers contained well-demarcated sarcoplasmic hyaline plaques of variable shape and size. These hyaline plaques depicted blue to purple in color with modified Gomori trichrome staining and positive Congo red staining but were devoid of any oxidative enzyme activity including NADH-TR, SDH, and COX. Immunohistochemical study with desmin antibody strongly highlighted these hyaline structures. Analysis of all five MFMD-genes including *ZASP*, *MYOT*, *DES*, *FLNC*, and *CRYAB* by using genomic DNA extracted from frozen muscle sample revealed no mutations. Neither muscle biopsy nor DNA of the patient's grandmother was available for study.

## Discussion

Limb-Girdle Muscular Dystrophy (LGMD) is a collective term used to describe patients with a heterogeneous group of autosomal dominant (LGMD1) or autosomal recessive (LGMD2) muscular dystrophies with the onset involving the pelvic or shoulder girdle muscles or both simultaneously<sup>(15)</sup>. Muscle biopsy displays dystrophic changes including variation in fiber size, necrosis and regeneration, and interstitial fibrosis. LGMD classification has been revolutionized with the advent of molecular genetics. To date, seven LGMD1 and 12 LGMD2 subtypes are reported<sup>(15,16)</sup>.

The present case developed progressive muscle weakness initially involving shoulder girdle and then pelvic girdle muscles. High serum CK level indicated damage of muscle tissue. Similar symptoms reported in the patient's grandmother hints autosomal dominant inheritance, although her clinicopathological data were not available. Based on this clinical picture, the patient was diagnosed clinically as LGMD1



**Fig. 1** Biopsy showed moderate variation in fiber size. On hematoxylin and eosin staining, abnormal muscle fibers contained sarcoplasmic hyaline plaques (A, H&E x 400) which appeared blue-green in color on modified Gomori trichrome staining (B, mGT x 400). These hyaline plaques were devoid of oxidative enzyme activities (C, NADH-TR x 400) and revealed positive Congo-red staining (D, Congo-red x 400). Immunohistochemistry study demonstrated strong expression of desmin immunoreactivity in these inclusions (E, Desmin x 400). A few fibers harbored rimmed vacuoles (F, mGT, x 400)

phenotype; however, muscle biopsy subsequently demonstrated a pathognomonic feature of MFM as mentioned earlier. The pathological finding prompts us to re-diagnose the current case as having MFM with limb-girdle phenotype. To the best of the authors' knowledge, the present case is the first Thai patient with MFM. Although currently the patient has no cardiac abnormalities, long-term follow-up of cardiac function is very crucial due to the common association of MFM with cardiomyopathy<sup>(2,3)</sup>.

As mentioned earlier, MFM is a pathologically defined group of hereditary skeletal muscle diseases and its clinical presentation is very variable. Weakness may preferentially affect limb-girdle muscle or distal muscle or may equally involve both muscle groups<sup>(3)</sup>. Clinical overlap of MFM and LGMD has been clearly demonstrated in patients with *MYOT* and *ZASP* mutations<sup>(7,9,17,18)</sup>. There is no definite genotype-phenotype correlation in patients with myotilinopathy and *ZASPopathy*<sup>(7,9,16,18)</sup>.

To date, less than half of MFM patients were found to have mutations in Z-disk related proteins

(*ZASP*, *MYOT*, *DES*, *FLNC* and *CRYAB*)<sup>(2)</sup>. There are no definite clinicopathological findings that could distinguish these mutation-identified MFM patients among each other. However, cataract is rather common in patients with *CRYAB* mutations. Patients harboring *DES* and *CRYAB* mutations may develop weakness since their 20's, while patients carrying *ZASP*, *MYOT* and *FLNC* likely experience weakness first in late adulthood or elderly. Molecular analysis of all five genes in the present case revealed no mutations. D' Amico A et al reported a 5-year-old girl carrying *LMNA* mutations with myopathological features mimicking MFM<sup>(19)</sup>. Although molecular analyses of *ZASP*, *MYOT*, *DES* and *CRYAB* were negative in this particular case, mutations of *FLNC* or other not-yet identified MFM-genes in the presented patient with laminopathy could not be excluded. For this particular reason, molecular analysis of *LMNA* was not conducted in the present case.

In conclusion, MFM is a distinct pathological entity with a wide range of phenotypic variations. The present case is the first Thai MFM patient with

LGMD1 phenotype in whom no mutations were found in all causative MFM-genes known to date. The present case emphasizes the importance of muscle biopsy in patients with LGMD1 and distal myopathy phenotypes to identify myofibrillar disorganization as a diagnostic clue of MFM. Cardiac monitor and prompt intervention is vital in decreasing the mortality rate among these patients. The molecular basis of mutation-negative MFM remains to be further elucidated.

#### Acknowledgements

The authors wish to thank Mr. Theeraphong Pho-iam, Ms. Naree Choosrichom, and Ms. Pimchanok Sehamo for their technical assistance.

#### References

1. Nakano S, Engel AG, Waclawik AJ, Emslie-Smith AM, Busis NA. Myofibrillar myopathy with abnormal foci of desmin positivity. I. Light and electron microscopy analysis of 10 cases. *J Neuropathol Exp Neurol* 1996; 55: 549-62.
2. Selcen D. Myofibrillar myopathies. *Curr Opin Neurol* 2008; 21: 585-9.
3. Selcen D, Ohno K, Engel AG. Myofibrillar myopathy: clinical, morphological and genetic studies in 63 patients. *Brain* 2004; 127: 439-51.
4. Selcen D, Engel AG. Myofibrillar myopathy [abstract]. *Neuromuscul Disord* 2007; 17: 832.
5. Selcen D, Engel AG. Myofibrillar myopathy. *GeneReviews* [homepage on the Internet]. 2005 [cited 2007 Jul 17]. Available from: <http://www.geneclinics.org>
6. Pestronk A. Myofibrillar myopathy. *Neuromuscular Disease Center* [homepage on the Internet]. 2005 [cited 2007 Jul 17]. St. Louis, MO: Washington University. Available from: <http://www.neuro.wustl.edu/neuromuscular>
7. Selcen D, Engel AG. Mutations in ZASP define a novel form of muscular dystrophy in humans. *Ann Neurol* 2005; 57: 269-76.
8. Griggs R, Vihola A, Hackman P, Talvinen K, Haravuori H, Faulkner G, et al. Zaspopathy in a large classic late-onset distal myopathy family. *Brain* 2007; 130: 1477-84.
9. Selcen D, Engel AG. Mutations in myotilin cause myofibrillar myopathy. *Neurology* 2004; 62: 1363-71.
10. Foroud T, Pankratz N, Batchman AP, Pauciulo MW, Vidal R, Miravalle L, et al. A mutation in myotilin causes spheroid body myopathy. *Neurology* 2005; 65: 1936-40.
11. Vorgerd M, van der Ven PF, Bruchertseifer V, Lowe T, Kley RA, Schroder R, et al. A mutation in the dimerization domain of filamin c causes a novel type of autosomal dominant myofibrillar myopathy. *Am J Hum Genet* 2005; 77: 297-304.
12. Shalaby S, Hayashi Y, Goto K, Nonaka I, Noguchi S, Nishino I, et al. Zaspopathy with multimimicores [abstract]. *Neuromuscul Disord* 2007; 17: 879.
13. Shalaby S, Hayashi Y, Goto K, Nonaka I, Noguchi S, Nishino I, et al. A novel myotilin mutation in exon 9: The first LGMD1A identified in Japan [abstract]. *Neuromuscul Disord* 2007; 17: 880.
14. Sangruchi T, Liewluck T. Myopathology a 14-year Siriraj experience: what have we learned? *Siriraj Hosp Gaz* 2003; 55: 368-80.
15. Ozawa E, Nonaka I. Limb-Girdle muscular dystrophy and related disorders. In: Katirji B, Kaminski HJ, Preston DC, Ruff RL, Shapiro BE, editors. *Neuromuscular disorders in clinical practice*. Massachusetts: Butterworth-Heinemann; 2002: 1049-71.
16. Pestronk A. Limb-Girdle muscular dystrophy. *Neuromuscular Disease Center* [homepage on the Internet]. 2005 [cited 2007 Jul 17]. St. Louis, MO: Washington University. Available from: <http://www.neuro.wustl.edu/neuromuscular>
17. Hauser MA, Horrigan SK, Salmikangas P, Torian UM, Viles KD, Dancel R, et al. Myotilin is mutated in limb girdle muscular dystrophy 1A. *Hum Mol Genet* 2000; 9: 2141-7.
18. Berciano J, Gallardo E, Dominguez-Perles R, Gallardo E, Garcia A, Garcia-Barredo R, et al. Autosomal-dominant distal myopathy with a myotilin S55F mutation: sorting out the phenotype. *J Neurol Neurosurg Psychiatry* 2008; 79: 205-8.
19. D'Amico A, Benedetti S, Petrini S, Sambuughin N, Boldrini R, Menditto I, et al. Major myofibrillar changes in early onset myopathy due to de novo heterozygous missense mutation in lamin A/C gene. *Neuromuscul Disord* 2005; 15: 847-50.



---

## รายงานผู้ป่วยไทยด้วยโรค myofibrillar myopathy ที่มีอาการกล้ามเนื้อต้นแขนและต้นขาอ่อนแรง

ธีริน ลิวลักษณ์, จุฑาทิพย์ คินทรักษ์, ตุ่มทิพย์ แสงรุจิ, Duygu Selcen, ก้องเกียรติ ภูณัทกันทรากร

Myofibrillar myopathy (MFM) เป็นกลุ่มโรคที่ประกอบด้วยโรคที่มีความหลากหลายทางคลินิก และ จีโนมกลายพันธุ์ที่เป็นสาเหตุการเกิดโรค พบทั้งชนิดถ่ายทอดทางพันธุกรรม และชนิดไม่ถ่ายทอดทางพันธุกรรม กลุ่มโรคนี้ มีลักษณะพยาธิสภาพที่จำเพาะ พบมีการสะสม myofibrillar degradation product ในเซลล์กล้ามเนื้อลาย และพบ การสะสมผิดปกติของโปรตีนหลายชนิดโดยเฉพาะ Z-disk related protein ผู้ป่วยด้วยโรค MFM มีอาการเบื้องต้น ของกล้ามเนื้ออ่อนแรง และมีโรคกล้ามเนื้อหัวใจร่วมด้วยในระยะต่อมา ปัจจุบันพบจีโนมกลายพันธุ์ที่เป็นสาเหตุ การเกิดโรคหลายชนิด ได้แก่ ZASP, MYOT, DES, FLNC และ CRYAB ผู้นิพนธ์รายงานกรณีศึกษา ผู้ป่วยหญิงไทย อายุ 29 ปี มีลักษณะทางคลินิกแบบ autosomal dominant limb-girdle muscular dystrophy (LGMD1) เนื่องจาก ย่าของผู้ป่วยมีอาการเช่นเดียวกับผู้ป่วย ภายหลังผู้ป่วยได้รับการวินิจฉัยเป็น MFM โดยลักษณะพยาธิสภาพของ กล้ามเนื้อ อย่างไรก็ตามไม่สามารถตรวจพบจีโนมกลายพันธุ์ชนิดที่เคยมีผู้รายงานไว้ในผู้ป่วยได้ รายงานผู้ป่วยรายนี้ แสดงให้เห็นว่าการตรวจ muscle biopsy มีความสำคัญในผู้ป่วยที่มีอาการ ทางคลินิกแบบ LGMD1 และ MFM เป็นโรคที่มีลักษณะหลากหลายทาง phenotype มาก น่าจะมีจีโนมกลายพันธุ์สาเหตุการเกิดโรคที่ยังไม่สามารถ ตรวจพบอีกหลายชนิด การตรวจการทำงานของหัวใจอย่างใกล้ชิดมีความสำคัญอย่างยิ่ง ในการป้องกันการเสียชีวิต ในผู้ป่วย MFM

---